The FDA gave Pfizer and Moderna until May 17 to propose changes to the labels of their COVID-19 vaccines or challenge the ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

After discussions with the FDA, Moderna has withdrawn its application for a combination shot, which had demonstrated efficacy ...

From a higher bar for regulatory clearance to pricing limitations, drug development is more expensive than ever. This has led ...

Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to ...

After a tense exchange, Senator Patty Murray (D-WA) told Kennedy that by implementing sweeping cuts to the HHS, he is ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.

The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination ...